{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:47Z","timestamp":1789644887863,"version":"4.0.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"vor","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jcin.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T14:22:41Z","timestamp":1503325361000},"page":"1621-1630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual\u00a0Antiplatelet\u00a0Therapy"],"prefix":"10.1016","volume":"10","author":[{"given":"Raffaele","family":"Piccolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Feres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Abizaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Gilard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong-Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2017.06.001_bib1","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2017.06.001_bib2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2017.06.001_bib3","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jcin.2017.06.001_bib4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(15)61220-X","article-title":"Stable coronary artery disease: revascularisation and invasive strategies","volume":"386","author":"Piccolo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2017.06.001_bib5","doi-asserted-by":"crossref","first-page":"e003587","DOI":"10.1161\/CIRCINTERVENTIONS.116.003587","article-title":"Dual antiplatelet therapy in percutaneous coronary intervention: a tale of 2 decades with new perspectives in the era of new-generation drug-eluting stents","volume":"9","author":"Piccolo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2017.06.001_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4244\/EIJY14M07_06","article-title":"Incidence, predictors, and impact of neurological events in non-ST-segment elevation acute coronary syndromes: the ACUITY trial","volume":"11","author":"Genereux","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2017.06.001_bib7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2017.06.001_bib8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2017.06.001_bib9","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2017.06.001_bib10","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A\u00a0new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2017.06.001_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2017.06.001_bib12","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2017.06.001_bib13","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2017.06.001_bib14","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2017.06.001_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2017.06.001_bib16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2017.06.001_bib17","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jama.299.5.532","article-title":"Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome","volume":"299","author":"Ho","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2017.06.001_bib18","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2017.06.001_bib19","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2017.06.001_bib20","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2017.06.001_bib21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2017.06.001_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jcin.2017.06.001_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4244\/EIJV11I1A11","article-title":"Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey","volume":"11","author":"Valgimigli","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2017.06.001_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098615588085","article-title":"Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs","volume":"6","author":"Ford","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jcin.2017.06.001_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pharmthera.2009.03.019","article-title":"Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence","volume":"123","author":"Lordkipanidze","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jcin.2017.06.001_bib26","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2017.06.001_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1538-7836.2010.04121.x","article-title":"Clopidogrel discontinuation and platelet reactivity following coronary stenting","volume":"9","author":"Mylotte","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2017.06.001_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00392-011-0310-7","article-title":"Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation","volume":"100","author":"Diehl","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jcin.2017.06.001_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/jcpt.12111","article-title":"Clopidogrel cessation triggers aspirin rebound in patients with coronary stent","volume":"39","author":"Djukanovic","year":"2014","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jcin.2017.06.001_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/09537104.2014.951318","article-title":"Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease","volume":"26","author":"Lordkipanidze","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2017.06.001_bib31","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/heartjnl-2011-300192","article-title":"Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study","volume":"97","author":"Sambu","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2017.06.001_bib32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacc.2013.10.018","article-title":"A\u00a0randomized controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease","volume":"63","author":"Ford","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2017.06.001_bib33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/CIRCINTERVENTIONS.110.937961","article-title":"The Platelet Activity After Clopidogrel Termination (PACT) study","volume":"3","author":"Frelinger","year":"2010","journal-title":"Circ Cardiovasc Interv"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879817311123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879817311123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:05:55Z","timestamp":1761847555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879817311123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":33,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1936879817311123"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2017.06.001","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual\u00a0Antiplatelet\u00a0Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}